Publications
Discover peer-reviewed publications by therapeutic area.
The information on this page pertains to select publication resources. It is not intended to serve as a comprehensive list of all publications resources.
If you would like to discover more educational content, please use the “Search” feature.
Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
The provision of this content is not intended to recommend or suggest use of its products in any manner inconsistent with local regulatory approval. For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Transthyretin Amyloidosis (ATTR)
Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy
Journal of the American College of Cardiology
Acute Hepatic Porphyria (AHP)
Patient experience with acute hepatic porphyria before and after long-term givosiran treatment in a qualitative interview study
Molecular Genetics and Metabolism Reports
Transthyretin Amyloidosis (ATTR)
Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy
JAMA Neurology
Transthyretin Amyloidosis (ATTR)
The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement
Orphanet Journal of Rare Diseases
Transthyretin Amyloidosis (ATTR)
Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis
Amyloid
Acute Hepatic Porphyria (AHP)
Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study
Orphanet Journal of Rare Diseases
Acute Hepatic Porphyria (AHP)
High disease burden and healthcare resource usage in patients with acute porphyria—A population-based analysis
Liver International
Primary Hyperoxaluria Type 1 (PH1)
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial
Frontiers in Pediatrics
